Royal Australian and New Zealand college of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary

Medical Journal of Australia

Volumn 208, Issue 5, 2018, Pages 219-225

  Malhi, Gin S ^a,b   Outhred, Tim ^a,b   Morris, Grace ^a,b   Boyce, Philip M ^c   Bryant, Richard ^d   Fitzgerald, Paul B ^e,f   Hopwood, Malcolm J ^g   Lyndon, Bill ^b,h   Mulder, Roger ⁱ   Murray, Greg ^j   Porter, Richard J ⁱ   Singh, Ajeet B ^k   Fritz, Kristina ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c University of Sydney   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e EPWORTH HEALTHCARE   (Australia)

^f Australia   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h Northside Clinic   (Australia)

ⁱ UNIVERSITY OF OTAGO   (New Zealand)

^j SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^k DEAKIN UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; BENZODIAZEPINE; CARBAMAZEPINE; CLOZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; LURASIDONE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ANTIDEPRESSANT AGENT; LITHIUM; NEUROLEPTIC AGENT; TRANQUILIZER;

ARTICLE; BIPOLAR DISORDER; COGNITIVE BEHAVIORAL THERAPY; ELECTROCONVULSIVE THERAPY; EVIDENCE BASED PRACTICE; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; PRACTICE GUIDELINE; PSYCHOTHERAPY; QUALITY OF LIFE; AUSTRALIA; MEDICAL SOCIETY; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; NEW ZEALAND; PROCEDURES; SECONDARY PREVENTION; SUICIDE;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; AUSTRALIA; BIPOLAR DISORDER; COMBINED MODALITY THERAPY; HUMANS; LITHIUM; MOOD DISORDERS; NEW ZEALAND; SECONDARY PREVENTION; SOCIETIES, MEDICAL; SUICIDE;

EID: 85043781721     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mja17.00658     Document Type: Article

References (52)

1. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet 2016; 387: 1561-1572.
2. Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet 2013; 381: 1672-1682.
3. Malhi GS, Bassett D, Boyce P, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015; 49: 1087-1206.
4. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder. Australian and New Zealand Clinical Practice Guidelines for the Treatment of Bipolar Disorder. Aust N Z J Psychiatry 2004; 38: 280-305.
5. Malhi GS, Outhred T, Hamilton A, et al. Royal Australian and New Zealand College of Psychiatrists mood disorder clinical practice guidelines: major depression summary. Med J Aust 2018; https://doi.org/10.5694/mja17.00659 [Epub ahead of print].
6. Mitchell PB, Slade T, Andrews G. Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey. Psychol Med 2004; 34: 777-785.
7. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: APA, 2013.
8. Vöhringer PA, Perlis RH. Discriminating between bipolar disorder and major depressive disorder. Psychiatr Clin North Am 2016; 39: 1-10.
9. Fritz K, Russell AM, Allwang C, et al. Is a delay in the diagnosis of bipolar disorder inevitable? Bipolar Disord 2017; 19: 396-400.
10. Schaffer A, Sinyor M, Reis C, et al. Suicide in bipolar disorder: characteristics and subgroups. Bipolar Disord 2014; 16: 732-740.
11. Young R, Biggs J, Ziegler V, Meyer D. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
12. Berk M, Malhi GS, Cahill C, et al. The Bipolar Depression Rating Scale (BDRS): its development, validation and utility. Bipolar Disord 2007; 9: 571-579.
13. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004; 6: 504-518.
14. Berk L, Jorm AF, Kelly CM, et al. Development of guidelines for caregivers of people with bipolar disorder: a Delphi expert consensus study. Bipolar Disord 2011; 13: 556-570.
15. Malhi G, Adams D, Lampe L, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl 2009; 119(439): 27-46.
16. Malhi GS, Bargh DM, Cashman E, et al. The clinical management of bipolar disorder complexity using astratified model. Bipolar Disord 2012; 14 Suppl 2: 66-89.
17. Nivoli AM, Murru A, Goikolea JM, et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 2012; 140: 125-141.
18. Vieta E, Panicali F, Goetz I, et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008; 106: 63-72.
19. Yildiz A, Vieta E, Leucht S, Baldessarini RJ. Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials. Neuropsychopharmacology 2011; 36: 375-389.
20. Schaffer CB, Schaffer LC, Miller AR, et al. Efficacy and safety of nonbenzodiazepine hypnotics for chronic insomnia in patients with bipolar disorder. J Affect Disord 2011; 128: 305-308.
21. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-151.
22. Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord 2014; 169 Suppl 1: S3-S11.
23. Pacchiarotti I, Mazzarini L, Colom F, et al. Treatment-resistant bipolar depression: towards a new definition. Acta Psychiatr Scand 2009; 120: 429-440.
24. McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry 2016; 3: 1138-1146.
25. Vieta E. Antidepressants in bipolar depression. Acta Psychiatr Scand 2008; 118: 335-336.
26. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64: 419-426.
27. Malhi GS, Adams D, Berk M. Medicating mood with maintenance in mind: bipolar depression pharmacotherapy. Bipolar Disord 2009; 11: 55-76.
28. Loo C, Katalinic N, Mitchell PB, Greenberg B. Physical treatments for bipolar disorder: a review of electroconvulsive therapy, stereotactic surgery and other brain stimulation techniques. J Affect Disord 2011; 132: 1-13.
29. Parikh SV, Hawke LD, Velyvis V, et al. Combined treatment: impact of optimal psychotherapy and medication in bipolar disorder. Bipolar Disord 2015; 17: 86-96.
30. Gitlin M, Frye MA. Maintenance therapies in bipolar disorders. Bipolar Disord 2012; 14: 51-65.
31. Connolly KR, Thase ME. The clinical management of bipolar disorder: a review of evidence-based guidelines. Primary Care Companion CNS Disord 2011; 13: PCC. 10r01097.
32. Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007; 9: 394-412.
33. Malhi GS, Bargh DM, McIntyre R, et al. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012; 14: 1-21.
34. Yatham LN, Fountoulakis KN, Rahman Z, et al. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. J Affect Disord 2013; 147: 365-372.
35. Carvalho AF, McIntyre RS, Dimelis D, et al. Predominant polarity as a course specifier for bipolar disorder: a systematic review. J Affect Disord 2014; 163: 56-64.
36. Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011; 13: 219-226.
37. Malhi GS, Gershon S, Outhred T. Lithiumeter: Version 2.0. Bipolar Disord 2016; 18: 631-641.
38. Malhi GS, Morris G, Hamilton A, et al. The ideal mood stabiliser: a quest for nirvana? Aust N Z Psychiatry 2017; 51: 434-435.
39. Malhi GS, Gessler D, Outhred T. The use of lithium for the treatment of bipolar disorder: recommendations from clinical practice guidelines. J Affect Disord 2017; 217: 266-280.
40. Benard V, Vaiva G, Masson M, Geoffroy P. Lithium and suicide prevention in bipolar disorder. Encéphale 2016; 42: 234-241.
41. Malhi GS, McAulay C, Gershon S, et al. The Lithium Battery: assessing the neurocognitive profile of lithium in bipolar disorder. Bipolar Disord 2016; 18: 102-115.
42. Malhi GS, Morris G, Hamilton A, et al. Defining the role of SGAs in the long-term treatment of bipolar disorder. Bipolar Disord 2017; 19: 65-67.
43. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006; 163: 217-224.
44. Morriss R, Faizal MA, Jones AP, et al. Interventions for helping people recognise early signs of recurrence in bipolar disorder. Cochrane Database Syst Rev 2007; 24 (1): CD004854.
45. Russell SJ, Browne JL. Staying well with bipolar disorder. Aust N Z J Psychiatry 2005; 39: 187-193.
46. Baldassano CF. Illness course, comorbidity, gender, and suicidality in patients with bipolar disorder. J Clin Psychiatry 2005; 67: 8-11.
47. Fountoulakis KN, Dimellis D. The treatment of rapid cycling bipolar disorder. In: Carvalho AF, Vieta E, editors. The treatment of bipolar disorder: integrative clinical strategies and future directions. Oxford: Oxford University Press, 2017.
48. Malhi G, Berk M, Morris G, et al. Mixed mood: the not so united states? Bipolar Disord 2017; 19: 242-245.
49. Olfson M, Mojtabai R, Merikangas K, et al. Reexamining associations between mania, depression, anxiety and substance use disorders: results from a prospective national cohort. Mol Psychiatry 2017; 22: 235-241.
50. Amann BL, Radua J, Wunsch C, et al. Psychiatric and physical comorbidities and their impact on the course of bipolar disorder: a prospective, naturalistic 4-year follow-up study. Bipolar Disord 2017; 19: 225-234.
51. Levin FR, Hennessy G. Bipolar disorder and substance abuse. Biol Psychiatry 2004; 56: 738-748.
52. Bassett D, Mulder R, Outhred T, et al. Defining disorders with permeable borders: you say bipolar, I say borderline! Bipolar Disord 2017; 19: 320-323.